Skip to main content
. 2017 Apr 26;8(28):45898–45917. doi: 10.18632/oncotarget.17438

Table 4C. OS.

Marker Median OS (months) HR (95% CI) p-value(log rank)
All patients 11.1
KRAS wt vs mut* 11.3 vs 10.6 0.8 (0.4-1.6) 0.55
BRAF wt vs mut# 10.2 vs 10.8 1.5 (0.5-5.2) 0.51
pERK1/2T202/Y204 < median vs > median 13.0 vs 9.8 2.7 (1.3-5.6) <0.01
pAKTS473 0+/1+ vs 2+/3+ 12.2 vs 10.4 1.5 (0.8-2.9) 0.22
pp70S6K1T389 < median vs > median 11.1 vs 10.4 1.2 (0.6-2.3) 0.52
KRAS wt/BRAF wt andpERK1/2T202/Y204 < median vs > median 19.6 vs 6.1 4.2 (1.2-15.1) 0.02
KRAS mut* or BRAF mut# andpERK1/2T202/Y204 < median vs > median 11.5 vs 7.8 3.2 (1.0-9.9) 0.03
KRAS wt/BRAF wt andpAKTS473 0+/1+ vs 2+/3+ 14.7 vs 9.5 2.0 (0.7-6.0) 0.20
KRAS mut* or BRAF mut# andpAKTS473 0+/1+ vs 2+/3+ 10.2 vs 10.8 1.0 (0.4-2.8) 0.97
KRAS wt/BRAF wt andpp70S6K1T389 < median vs > median 19.6 vs 9.5 1.4 (0.5-4.0) 0.50
KRAS mut* or BRAF mut# andpp70S6K1T389 < median vs > median 10.8 vs 7.8 1.9 (0.6-5.9) 0.25

*exon 2; #exon 15.